Ionis Pharmaceuticals, Inc. (IONS) announced that Pfizer (PFE) reported positive results from Phase 2b clinical study of vupanorsen.
Pfizer (PFE) has kicked off a Phase 2b study of vupanorsen (ANGPTL3) in statin-treated patients with elevated non-high-density lipoprotein cholesterol and triglycerides (TGs). …
In a previous article, I talked about the so-called patent cliff and the correlation to the pace of mergers and acquisitions in the pharma …
Ionis Pharmaceuticals Inc (NASDAQ:IONS) shares are tumbling nearly 11% in Monday’s trading session, after the drug maker announced mixed results from a Phase 3 …
Ionis Pharmaceuticals Inc (NASDAQ:IONS) reported that it outperformed its financial guidance by ending 2016 with pro forma operating income of $25.8 million and $665.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced the advancement of IONIS-FXIRx in clinical development under an existing exclusive license agreement with Bayer.
Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced that the Company expects to significantly improve upon its 2016 financial guidance. Ionis expects to end 2016 with …
Ionis Pharmaceuticals Inc (NASDAQ:IONS) shares were initially up 6% this morning after the biotech firm and its wholly-owned subsidiary Akcea Therapeutics signed an …
Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Akcea Therapeutics, a wholly-owned subsidiary of Ionis, announced an exclusive, worldwide option and collaboration agreement with Novartis to …
Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced positive data from a Phase 2 study of IONIS-GCGRRx in 79 patients with type 2 diabetes. In this …
